121 related articles for article (PubMed ID: 1571217)
1. Immune status of children on continuous ambulatory peritoneal dialysis.
Hisano S; Miyazaki C; Hatae K; Kaku Y; Yamane I; Ueda K; Okamua S
Pediatr Nephrol; 1992 Mar; 6(2):179-81. PubMed ID: 1571217
[TBL] [Abstract][Full Text] [Related]
2. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE
Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116
[TBL] [Abstract][Full Text] [Related]
3. Response to measles-mumps-rubella vaccine in children on dialysis.
Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
[TBL] [Abstract][Full Text] [Related]
4. Lymphocytes subsets in the course of continuous ambulatory peritoneal dialysis (CAPD).
Griveas I; Visvardis G; Fleva A; Papadopoulou D; Mitsopoulos E; Nikopoulos K; Manou E; Kyriklidou P; Ginikopoulou E; Meimaridou D; Pavlitou A; Sakellariou G
Ren Fail; 2004 Nov; 26(6):641-6. PubMed ID: 15600255
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
Just M; Berger R; Just V
Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863
[TBL] [Abstract][Full Text] [Related]
7. Are uraemic children immunologically compromised?
Ensari C; Ekim M; Ikinciogullari A; Tümer N; Ensari A
Nephron; 2001 Aug; 88(4):379-81. PubMed ID: 11474235
[TBL] [Abstract][Full Text] [Related]
8. Measles, mumps, and rubella antibodies in vaccinated Baltimore children.
King JC; Lichenstein R; Feigelman S; Luna C; Permutt TJ; Patel J
Am J Dis Child; 1993 May; 147(5):558-60. PubMed ID: 8488803
[TBL] [Abstract][Full Text] [Related]
9. [Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine].
Takayama N; Kidokoro M; Suzuki K; Morita M
Kansenshogaku Zasshi; 1992 Jun; 66(6):776-80. PubMed ID: 1331262
[TBL] [Abstract][Full Text] [Related]
10. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
Gerike E; Tischer A
Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
[TBL] [Abstract][Full Text] [Related]
11. Measles, mumps and rubella: control by vaccination.
van Druten JA; de Boo T; Plantinga AD
Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
[TBL] [Abstract][Full Text] [Related]
12. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
[TBL] [Abstract][Full Text] [Related]
13. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
André FE; Peetermans J
Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770
[TBL] [Abstract][Full Text] [Related]
14. Prospective comparison of blood and peritoneal lymphocytes from continuous ambulatory peritoneal dialysis patients.
Lewis SL; Bonner PN; Cooper CL; Holmes CJ
J Clin Lab Immunol; 1992 Jan; 37(1):3-19. PubMed ID: 1339234
[TBL] [Abstract][Full Text] [Related]
15. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
16. Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children.
Hiltunen M; Hyöty H; Leinikki P; Akerblom HK; Tuomilehto J; Vesikari T
Diabet Med; 1994 Dec; 11(10):942-6. PubMed ID: 7895458
[TBL] [Abstract][Full Text] [Related]
17. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
Dennehy PH; Saracen CL; Peter G
Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
[TBL] [Abstract][Full Text] [Related]
18. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with a combined vaccine against measles, mumps and rubella aiming at elimination of the three diseases.
Böttiger M; Christenson B; Strandell A; Romanus V
Dev Biol Stand; 1986; 65():37-43. PubMed ID: 3556776
[TBL] [Abstract][Full Text] [Related]
20. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
Perez EE; Bokszczanin A; McDonald-McGinn D; Zackai EH; Sullivan KE
Pediatrics; 2003 Oct; 112(4):e325. PubMed ID: 14523220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]